Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004185:Disability Evaluation; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006680:HLA Antigens / Q000097:blood*; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy*; D018709:Statistics, Nonparametric; D013997:Time Factors
D000970:Antineoplastic Agents; D006680:HLA Antigens; D000068576:Interferon beta-1b; D016899:Interferon-beta